This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01580/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01580/identifier/drugbank/
n6http://linked.opendata.cz/resource/mesh/concept/
n20http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01580/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01580/identifier/wikipedia/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01580/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01580/identifier/bindingdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01580/identifier/pubchem-compound/
n19http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01580
rdf:type
n3:Drug
n3:description
A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety. [PubChem]
n3:generalReferences
# McDevitt DG: Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J. 1987 Dec;8 Suppl M:9-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2897304
n3:group
approved
n3:halfLife
1-2 hours
n3:indication
Used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
owl:sameAs
n12:DB01580 n20:DB01580
dcterms:title
Oxprenolol
adms:identifier
n8:PA10284 n9:4470 n10:DB01580 n13:4631 n14:46508996 n15:Oxprenolol n16:50240370
n3:mechanismOfAction
Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Oxprenolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
n3:synonym
Oxprenolol Oxprenololum
n3:toxicity
Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
n17:hasAHFSCode
n18:24-24-00
n3:foodInteraction
Avoid alcohol. Avoid natural licorice. Take without regard to meals.
n3:salt
n5:hasConcept
n6:M0015659
n3:IUPAC-Name
n4:271B57DB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B57E1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B57E0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B57DD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B57DE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B57DF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B57D9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B57F1-363D-11E5-9242-09173F13E4C5 n4:271B57DA-363D-11E5-9242-09173F13E4C5 n4:271B57D7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B57D8-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n19:C07AA02
n3:H-Bond-Acceptor-Count
n4:271B57E7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B57E8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B57E2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B57E3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B57E5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B57E4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B57E6-363D-11E5-9242-09173F13E4C5
n3:absorption
Oral bioavailability is 20-70%.
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B57F2-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
6452-71-7
n3:category
n3:Bioavailability
n4:271B57ED-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B57EF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B57F0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B57EC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B57EB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B57EE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B57DC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B57E9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B57EA-363D-11E5-9242-09173F13E4C5